NAV

Sirpiglenastat

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Sirpiglenastat
DrugBank Accession Number
DB17536
Background

Sirpiglenastat, also known as DRP-104, is a prodrug of 6-diazo-5-oxo-L-norleucine (DON), which is a broad-acting glutamine antagonist. It is under investigation in clinical trial NCT04471415 (Study to Investigate DRP-104 in Adults With Advanced Solid Tumors).

Type
Small Molecule
Groups
Investigational
Structure
3D
Similar Structures
Weight
Average: 441.488
Monoisotopic: 441.201218989
Chemical Formula
C22H27N5O5
Synonyms
  • (-)-sirpiglenastat
  • (s)-isopropyl 2-((s)-2-acetamido-3-(1h-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate
  • L-norleucine, n-acetyl-l-tryptophyl-6-diazo-5-oxo-, 1-methylethyl ester
  • Propan-2-yl (2s)-2-((n-acetyl-l-tryptophyl)amino)-6-diazo-5-oxohexanoate
External IDs
  • DRP-104
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
9GGE6A0ZMK
CAS number
2079939-05-0
InChI Key
LQNMCWOJACNQQM-PMACEKPBSA-N
InChI
InChI=1S/C22H27N5O5/c1-13(2)32-22(31)19(9-8-16(29)12-25-23)27-21(30)20(26-14(3)28)10-15-11-24-18-7-5-4-6-17(15)18/h4-7,11-13,19-20,24H,8-10H2,1-3H3,(H,26,28)(H,27,30)/t19-,20-/m0/s1
IUPAC Name
propan-2-yl (2S)-6-diazo-2-[(2S)-2-acetamido-3-(1H-indol-3-yl)propanamido]-5-oxohexanoate
SMILES
CC(C)OC(=O)[C@H](CCC(=O)C=[N+]=[N-])NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(C)=O

References

General References
Not Available
ChemSpider
115009349
ChEMBL
CHEMBL4650367

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1, 2RecruitingTreatmentFibrolamellar Hepatocellular Carcinoma1
1, 2TerminatedTreatmentAdvanced Solid Tumors / Metastatic Non-Small Cell Lung Cancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0344 mg/mLALOGPS
logP2.13ALOGPS
logP-0.064Chemaxon
logS-4.1ALOGPS
pKa (Strongest Acidic)8.99Chemaxon
pKa (Strongest Basic)-1.9Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count5Chemaxon
Hydrogen Donor Count3Chemaxon
Polar Surface Area134.43 Å2Chemaxon
Rotatable Bond Count12Chemaxon
Refractivity114.78 m3·mol-1Chemaxon
Polarizability45.49 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Drug created at February 15, 2023 17:51 / Updated at February 16, 2023 16:06